FIA
TXG icon

FNY Investment Advisers’s 10x Genomics TXG Stock Holding History

FNY Investment Advisers’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-200
Closed -$10K – 1079
2019
Q3 		$10K Buy
+200
New +$11.1K ﹤0.01% 587

Other funds holding TXG

FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
JCM
JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

FNY Investment Advisers's TXG Position: Q4 2019 in Review

FNY Investment Advisers sold out of 10x Genomics (TXG) in Q4 2019, closing a stake of 200 shares — an estimated $10K sold.

FNY Investment Advisers first reported a position in TXG in Q3 2019 and held it in 1 quarter. The position peaked at $10K in Q3 2019. 85 funds tracked by Wall St. Rank hold TXG as of Q4 2019.

  • FNY Investment Advisers reported no remaining 10x Genomics position as of Q4 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 200 10x Genomics shares in Q4 2019, an estimated $10K.
  • FNY Investment Advisers first reported a position in 10x Genomics in Q3 2019 and held it in 1 quarter.
  • FNY Investment Advisers's 10x Genomics position peaked at $10K in Q3 2019.
  • 85 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2019.

Based on FNY Investment Advisers's 13F filing for Q4 2019, filed 10 Jan 2020.